Harness the Power of Science to Cure Cancer.
Total raised: $7.5M
Funding Rounds 1
| Date | Series | Amount | Investors |
| 01.07.2024 | Series A | $7.5M | - |
Mentions in press and media 10
| Date | Title | Description |
| 30.09.2024 | The Rising Tide of Chinese Biopharmaceuticals: A Global Perspective | The biopharmaceutical landscape is shifting. Chinese companies are no longer just local players; they are emerging as global contenders. The recent collaboration between Anbogen and BeiGene exemplifies this trend. Anbogen, a clinical-stage ... |
| 27.09.2024 | Anbogen Announces Drug Supply Collaboration with BeiGene to Evaluate Combination Therapy in Colorectal Cancer | TAIPEI, Sept. 27, 2024 /PRNewswire/ -- Anbogen, a clinical-stage biotech company, today announced a drug supply collaboration to evaluate the combination of Anbogen's HDAC inhibitor, ABT-301, with BeiGene's anti-PD-1 antibody tislelizumab, ... |
| 01.07.2024 | Anbogen Therapeutics Raises USD 7.5M in Series A+ Funding | Anbogen Therapeutics, Inc., a Taipei, Taiwan-based clinical-stage company developing cancer therapies, raised USD 7.3M in Series A+ funding. The round was led by KGI Venture Capital and both new and existing investors. The company intends t... |
| 02.02.2024 | Deals in brief: Hukumonline, Pintar, and Pixelmon secure funding, Singapore’s GIC invests in Zum, seven China deals, and more | Hukumonline receives Series B funding from Indonesia’s MDIF Hukumonline, a resource portal for law and regulation in Indonesia, has secured an undisclosed sum in Series B funding from Indonesia’s Media Development Investment Fund. Establish... |
| 01.02.2024 | Deals in brief: Silverstrand Capital invests in Porifera, Amber Electric and Anbogen secure funding, ten China and India deals, and more | Silverstrand Capital invests in Porifera The Singapore-based family office has invested an undisclosed amount in Porifera, a California-based technology company specializing in the development of forward osmosis membrane solutions. This inv... |
| 01.02.2024 | Anbogen Raises 12.5M in Series A Funding | Anbogen Therapeutics, a Taipei, Taiwan-based clinical-stage biotechnology company, raised $12.5M in Series A funding. The round was led by China Development Industrial Bank (CDIB), with participation from Taian Venture Capital, Maxpro and t... |
| 01.02.2024 | Anbogen Secures 12.5 Million in Series A Funding, Advancing Precision Oncology Drug Development | TAIPEI, Feb. 1, 2024 /PRNewswire/ -- Anbogen Therapeutics, a clinical-stage biotechnology company specializing in groundbreaking cancer drug development, today announced the successful completion of its Series A funding round. The lead inve... |
| 13.09.2022 | AnBogen Therapeutics Receives Approval from U.S. FDA for Phase Ib/II Protocol Amendment for ABT-101 | An oral Tyrosine Kinase Inhibitor of HER2 Exon20 Insertion, for the Treatment of Non-Small Cell Lung Cancer TAIPEI, Sept. 13, 2022 /PRNewswire/ -- AnBogen Therapeutics, a clinical-stage biotech company designing and developing precision onc... |
| - | AnBogen Therapeutics | “安邦生技 Anbogen Therapeutics” |
| - | AnBogen Therapeutics | “Dedicate to creating breakthrough science that changes the life of cancer patients.” |